Navigation Links
Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)

JERUSALEM, June 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (, a developer of oral delivery systems, announced today that it has been selected to display its abstract, entitled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects, at the upcoming 68th Annual American Diabetes Association's Scientific Sessions Conference in San Francisco, highlighting the successful results from its oral insulin trials on healthy volunteers.

The abstract will also be printed in the Scientific Sessions Abstract Book, the June 2008 supplement to the journal Diabetes.

Oramed's technology will be included in an oral presentation by Prof. Dr. Lutz Heinemann, CEO of Profil Institute for Metabolic Research, "Pharmacokinetics and Pharmacodynamics of Alternate Insulin Delivery Systems," on Saturday, June 7, 2008 from 4 pm to 6 pm.

"The selection of Oramed as one of the companies to exhibit at Scientific Sessions is a great opportunity that allows us to present our data from human trials to the leading scientists in the diabetes field from all over the world," said Nadav Kidron, Oramed CEO.

Oramed's abstract poster has been assigned presentation number 425-P Clinical Therapeutics/New Technology - Insulin Delivery Systems and is available for viewing throughout the conference. A representative of the company will be available to answer questions on Saturday, June 7 from 6-7PM and from 12-2PM on Monday, June 9 at San Francisco's Moscone Convention Center, Hall D.

For more information about the ADA and the upcoming conference, please visit

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals,

Eric Rosenberg,

Cell: +972-54-566-7713,

Office: +972-2-566-0001,

Email: .

Media Contacts:

Ruder Finn Israel for Oramed,

Matthew Krieger,

Cell: +972-54-467-6950,

Office: +972-2-589-2003,

Email: .

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
3. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
4. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
5. VIA Pharmaceuticals to Present at Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
6. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
7. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
8. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
9. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
10. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
11. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
Post Your Comments:
(Date:11/23/2015)... ... 2015 , ... Noblis, Inc., a leading provider of science, technology, and strategy ... Intelligence Agency (NGA), has joined the Noblis NSP team as President of the organization. ... community and the private sector,” said L. Roger Mason, Jr., Ph.D. , Senior ...
(Date:11/23/2015)... and PISCATAWAY, New Jersey , ... Crystallographic Data Centre (CCDC) announces the launch ... Database (CSD) and the CSD-System, now complemented by ... CSD-Discovery to support the discovery of new molecules, ... CSD-Enterprise, the complete set of the CCDC,s applications ...
(Date:11/23/2015)... -- CryoLife, Inc. (NYSE: CRY ), a leading medical device ... announced today that it will participate in the upcoming 27 ... 2, 2015 at The New York Palace Hotel in ... , President and Chief Executive Officer. --> ... --> A live webcast of the Company,s presentation is ...
(Date:11/23/2015)... , Nov. 23, 2015  Oxis Biotech, Inc. ... Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced ... Masonic Cancer Center received notification from the U.S. ... proceed with their planned combination Phase 1/Phase 2 ... rights to develop and commercialize OXS-1550, a novel ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
Breaking Biology News(10 mins):